FDA Cracks Down on Misleading Drug Ads in Major Pharmaceutical Companies
The FDA has begun a crackdown on misleading drug advertisements, issuing thousands of letters to pharmaceutical companies, including Lilly, Novartis, and BMS, to remove non-compliant ads and bring promotional materials into compliance.
The FDA is enforcing a 'fair balance' requirement in drug ads, emphasizing clear presentation of both benefits and risks.
Approximately 100 cease-and-desist letters were sent to companies with deceptive ads, as part of a broader effort to improve transparency and accountability in pharmaceutical marketing.